Name | Number of supported studies | Average coverage | |
---|---|---|---|
peripheral blood | 11 studies | 23% ± 6% | |
lung | 8 studies | 28% ± 6% | |
intestine | 5 studies | 28% ± 8% | |
lymph node | 5 studies | 29% ± 12% | |
uterus | 4 studies | 23% ± 6% | |
kidney | 3 studies | 25% ± 4% | |
bone marrow | 3 studies | 21% ± 8% | |
breast | 3 studies | 22% ± 2% | |
prostate | 3 studies | 28% ± 1% | |
liver | 3 studies | 26% ± 10% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
lung | 100% | 5635.71 | 578 / 578 | 85% | 36.41 | 983 / 1155 |
stomach | 100% | 4094.42 | 359 / 359 | 84% | 36.42 | 240 / 286 |
intestine | 100% | 4455.09 | 966 / 966 | 80% | 25.94 | 424 / 527 |
kidney | 96% | 2715.21 | 85 / 89 | 83% | 57.93 | 750 / 901 |
esophagus | 94% | 1459.65 | 1364 / 1445 | 79% | 45.41 | 145 / 183 |
pancreas | 80% | 1250.84 | 262 / 328 | 88% | 53.39 | 156 / 178 |
breast | 94% | 1412.49 | 433 / 459 | 67% | 16.85 | 754 / 1118 |
prostate | 96% | 1793.76 | 235 / 245 | 61% | 10.96 | 305 / 502 |
bladder | 95% | 1576.52 | 20 / 21 | 59% | 16.47 | 297 / 504 |
uterus | 88% | 1005.38 | 150 / 170 | 63% | 34.98 | 291 / 459 |
liver | 77% | 2399.80 | 175 / 226 | 68% | 31.17 | 275 / 406 |
thymus | 81% | 982.23 | 527 / 653 | 55% | 13.72 | 330 / 605 |
skin | 79% | 1440.12 | 1429 / 1809 | 46% | 13.28 | 215 / 472 |
lymph node | 0% | 0 | 0 / 0 | 100% | 134.88 | 29 / 29 |
spleen | 100% | 7836.71 | 241 / 241 | 0% | 0 | 0 / 0 |
adipose | 97% | 1724.03 | 1168 / 1204 | 0% | 0 | 0 / 0 |
blood vessel | 87% | 1020.41 | 1167 / 1335 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 87% | 49.88 | 39 / 45 |
ovary | 44% | 351.78 | 80 / 180 | 42% | 7.64 | 179 / 430 |
peripheral blood | 84% | 6507.66 | 778 / 929 | 0% | 0 | 0 / 0 |
heart | 78% | 945.92 | 671 / 861 | 0% | 0 | 0 / 0 |
adrenal gland | 54% | 641.11 | 140 / 258 | 12% | 1.61 | 27 / 230 |
muscle | 32% | 215.77 | 257 / 803 | 0% | 0 | 0 / 0 |
brain | 13% | 90.99 | 332 / 2642 | 10% | 1.91 | 70 / 705 |
eye | 0% | 0 | 0 / 0 | 1% | 0.11 | 1 / 80 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_0007283 | Biological process | spermatogenesis |
GO_2000116 | Biological process | regulation of cysteine-type endopeptidase activity |
GO_0007249 | Biological process | canonical NF-kappaB signal transduction |
GO_0060544 | Biological process | regulation of necroptotic process |
GO_0050727 | Biological process | regulation of inflammatory response |
GO_0045088 | Biological process | regulation of innate immune response |
GO_0039535 | Biological process | regulation of RIG-I signaling pathway |
GO_0042981 | Biological process | regulation of apoptotic process |
GO_0043066 | Biological process | negative regulation of apoptotic process |
GO_0060546 | Biological process | negative regulation of necroptotic process |
GO_0043123 | Biological process | positive regulation of canonical NF-kappaB signal transduction |
GO_0070424 | Biological process | regulation of nucleotide-binding domain, leucine rich repeat containing receptor signaling pathway |
GO_0006915 | Biological process | apoptotic process |
GO_0031398 | Biological process | positive regulation of protein ubiquitination |
GO_0038061 | Biological process | non-canonical NF-kappaB signal transduction |
GO_0034121 | Biological process | regulation of toll-like receptor signaling pathway |
GO_0033209 | Biological process | tumor necrosis factor-mediated signaling pathway |
GO_0051726 | Biological process | regulation of cell cycle |
GO_0007166 | Biological process | cell surface receptor signaling pathway |
GO_0032991 | Cellular component | protein-containing complex |
GO_0005654 | Cellular component | nucleoplasm |
GO_0005829 | Cellular component | cytosol |
GO_0005737 | Cellular component | cytoplasm |
GO_0005634 | Cellular component | nucleus |
GO_0061630 | Molecular function | ubiquitin protein ligase activity |
GO_0043027 | Molecular function | cysteine-type endopeptidase inhibitor activity involved in apoptotic process |
GO_0044877 | Molecular function | protein-containing complex binding |
GO_0016740 | Molecular function | transferase activity |
GO_0046872 | Molecular function | metal ion binding |
GO_0004842 | Molecular function | ubiquitin-protein transferase activity |
GO_0005515 | Molecular function | protein binding |
Gene name | BIRC3 |
Protein name | Alternative protein BIRC3 Baculoviral IAP repeat containing 3 Baculoviral IAP repeat-containing protein 3 (EC 2.3.2.27) (Apoptosis inhibitor 2) (API2) (Cellular inhibitor of apoptosis 2) (C-IAP2) (IAP homolog C) (Inhibitor of apoptosis protein 1) (hIAP-1) (hIAP1) (RING finger protein 49) (RING-type E3 ubiquitin transferase BIRC3) (TNFR2-TRAF-signaling complex protein 1) |
Synonyms | RNF49 API2 MIHC |
Description | FUNCTION: Multi-functional protein which regulates not only caspases and apoptosis, but also modulates inflammatory signaling and immunity, mitogenic kinase signaling and cell proliferation, as well as cell invasion and metastasis. Acts as an E3 ubiquitin-protein ligase regulating NF-kappa-B signaling and regulates both canonical and non-canonical NF-kappa-B signaling by acting in opposite directions: acts as a positive regulator of the canonical pathway and suppresses constitutive activation of non-canonical NF-kappa-B signaling. The target proteins for its E3 ubiquitin-protein ligase activity include: RIPK1, RIPK2, RIPK3, RIPK4, CASP3, CASP7, CASP8, IKBKE, TRAF1, and BCL10. Acts as an important regulator of innate immune signaling via regulation of Toll-like receptors (TLRs), Nodlike receptors (NLRs) and RIG-I like receptors (RLRs), collectively referred to as pattern recognition receptors (PRRs). Protects cells from spontaneous formation of the ripoptosome, a large multi-protein complex that has the capability to kill cancer cells in a caspase-dependent and caspase-independent manner. Suppresses ripoptosome formation by ubiquitinating RIPK1 and CASP8. . |
Accessions | Q13489 H0YCJ5 ENST00000673846.1 ENST00000527309.2 ENST00000263464.9 ENST00000532808.5 L8E7L9 ENST00000526421.6 A0A669KBC7 |